Study guide
6.3 Common Dermatological & Psychiatric Manifestations in Internal Medicine
Combined Medical Services Examination UPSC CMS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Logistics & Pattern
1.1 UPSC CMS Examination Overview & Eligibility 1.2 Two-Paper Written Exam Pattern & Negative Marking 1.3 Personality Test, Service Allocation & Career Paths
2 Chapter 2: General Medicine - Cardiology & Respiratory
2.1 Coronary Artery Disease & Acute Myocardial Infarction 2.2 Heart Failure & Cardiac Arrhythmias 2.3 Community-Acquired Pneumonia & Pulmonary Tuberculosis 2.4 COPD, Bronchial Asthma & Pulmonary Embolism
3 Chapter 3: General Medicine - Gastroenterology & Hepatology
3.1 Peptic Ulcer Disease & Upper GI Bleeding 3.2 Liver Cirrhosis & Portal Hypertension 3.3 Acute & Chronic Viral Hepatitis & Pancreatitis 3.4 Inflammatory Bowel Disease & Malabsorption Syndromes
4 Chapter 4: General Medicine - Nephrology & Endocrinology
4.1 Acute Kidney Injury & Chronic Kidney Disease 4.2 Glomerulonephritis, Nephrotic Syndrome & Electrolyte Imbalances 4.3 Diabetes Mellitus: Diagnosis, Complications & Management 4.4 Thyroid Disorders & Adrenal Gland Dysfunction
5 Chapter 5: General Medicine - Neurology, Haematology & Infection
5.1 Cerebrovascular Accidents (Stroke) & Epilepsy 5.2 Approach to Anaemia: Microcytic, Megaloblastic & Haemolytic 5.3 Acute & Chronic Leukaemias and Lymphomas 5.4 Tropical & Endemic Infections: Malaria, Typhoid & Dengue
6 Chapter 6: General Medicine - Emergency Medicine & Toxicology
6.1 Acute Anaphylaxis, Sepsis & Cardiopulmonary Resuscitation 6.2 Organophosphate, Paracetamol & Snakebite Toxicology 6.3 Common Dermatological & Psychiatric Manifestations in Internal Medicine 6.4 Musculoskeletal System & Adult Rheumatology
7 Chapter 7: Paediatrics - Neonatology & Child Growth
7.1 Newborn Care, Neonatal Resuscitation & APGAR Score 7.2 Prematurity, Low Birth Weight & Neonatal Jaundice 7.3 Infant & Child Growth & Developmental Milestones
8 Chapter 8: Paediatrics - Child Health & Nutrition
8.1 Protein-Energy Malnutrition (PEM) & Micronutrient Deficiencies 8.2 Universal Immunization Programme (UIP) & Child Vaccines 8.3 Pediatric Diarrhoea, Dehydration & Respiratory Emergencies 8.4 Birth Defects, Genetic Counseling, Autism & Paediatric Accidents/Poisoning
9 Chapter 9: Surgery - General Surgery, Wounds & Shock
9.1 Wound Healing, Surgical Site Infections & Gas Gangrene 9.2 Pathophysiology of Shock & Perioperative Fluid Therapy 9.3 Acute Abdomen: Appendicitis, Peritonitis & Intestinal Obstruction 9.4 Classification, Resuscitation & Management of Thermal Burns 9.5 Medicolegal & Ethical Issues in Surgery
10 Chapter 10: Surgery - Surgical Specialties I
10.1 Inguinal, Femoral & Ventral Hernias 10.2 Benign Breast Diseases & Breast Carcinoma 10.3 Solitary Thyroid Nodule & Thyroid Carcinoma 10.4 Benign Prostatic Hyperplasia & Renal Calculi
11 Chapter 11: Surgery - ENT, Orthopaedics & Anaesthesia
11.1 Acute Otitis Media, Tonsillitis & Epistaxis 11.2 Cataract, Glaucoma & Red Eye Emergencies 11.3 Principles of Fracture Management & Common Dislocation 11.4 Principles of Local, Regional & General Anaesthesia 11.5 Neurosurgery: Raised ICP, Head Injury & CNS Lesions 11.6 Thoracic Surgery: Chest Trauma, Pleural & Lung Disease
12 Chapter 12: Obstetrics - Antenatal Care & Complications
12.1 Antenatal Care, Maternal Nutrition & Fetal Assessment 12.2 Preeclampsia, Eclampsia & Gestational Hypertension 12.3 Antepartum Haemorrhage: Placenta Previa & Abruptio Placentae 12.4 Anemia in Pregnancy & Gestational Diabetes Mellitus 12.5 Spontaneous & Recurrent Abortion: Recognition & Management
13 Chapter 13: Obstetrics & Gynaecology - Labor & PPH
13.1 Normal Labor Mechanisms & Partograph Monitoring 13.2 Malpresentations, Breech & Obstructed Labor 13.3 Postpartum Haemorrhage (PPH) Causes & Management 13.4 Puerperal Sepsis & Postnatal Maternal Care
14 Chapter 14: Gynaecology & Family Planning
14.1 Abnormal Uterine Bleeding & Uterine Fibroids 14.2 Cervical Screening (Pap Smear) & Pelvic Inflammatory Disease 14.3 Temporary & Permanent Contraceptive Methods in India 14.4 Medical Termination of Pregnancy (MTP): Law & Methods
15 Chapter 15: PSM - Epidemiology & Biostatistics
15.1 Principles of Epidemiology & Disease Transmission 15.2 Observational & Experimental Epidemiological Study Designs 15.3 Evaluation of Screening Tests: Sensitivity, Specificity & Predictive Value 15.4 Biostatistics: Sampling, Central Tendency & Significance Testing
16 Chapter 16: PSM - Disease Epidemiology & Programmes
16.1 Epidemiology & Control of TB, Malaria & Dengue 16.2 National Tuberculosis Elimination Programme & NVBDCP 16.3 Epidemiology of Hypertension, Diabetes & Cancer in India 16.4 Cold Chain Management & Vaccine Logistics in India 16.5 Genetics and Health: Inheritance, Screening & Counseling
17 Chapter 17: PSM - Health Planning & Environmental Health
17.1 Demography, Fertility Rates & Family Welfare Indicators 17.2 Safe Water Supply, Waste Disposal & Air Pollution 17.3 Occupational Health Hazards & Pneumoconioses 17.4 Health Care Delivery System, Ayushman Bharat & National Health Mission 17.5 International Health: WHO, Global Agencies & SDG 3 17.6 Medical Sociology & Health Education
6.3 Common Dermatological & Psychiatric Manifestations in Internal Medicine
Key Takeaways Explain This Topic AI
Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) represent a spectrum of severe mucocutaneous reactions defined by total body surface area (TBSA) of epidermal detachment: SJS < 10%, SJS/TEN overlap 10–30%, and TEN > 30%, exhibiting a positive Nikolsky sign.
Erythema Nodosum is a septal panniculitis presenting as painful, tender erythematous nodules on the anterior shins; it is a major cutaneous marker for Sarcoidosis (Löfgren syndrome), Tuberculosis, Streptococcal infection, and Inflammatory Bowel Disease.
Delirium is an acute, fluctuating disturbance of attention and level of consciousness caused by underlying organic medical conditions, distinguishing it from Dementia which is characterized by chronic, progressive cognitive decline with preserved consciousness.
Neuroleptic Malignant Syndrome (NMS) is caused by dopamine D2 receptor blockade, featuring hyperthermia, severe "lead-pipe" muscle rigidity, autonomic instability, and extreme Creatine Kinase (CK) elevation, treated with Dantrolene or Bromocriptine.
Serotonin Syndrome is triggered by excessive serotonergic activity and is clinically differentiated from NMS by hyperreflexia, ocular/inducible clonus, hyperactive bowel sounds, and rapid onset (< 24 hours), managed with Cyproheptadine.
Last updated: July 2026
Common Dermatological & Psychiatric Manifestations in Internal Medicine
Cutaneous markers of systemic disease and acute neuropsychiatric emergencies frequently appear on UPSC CMS examination papers. Mastering severe cutaneous adverse reactions, systemic dermatoses, delirium, and life-threatening toxidromes like Neuroleptic Malignant Syndrome and Serotonin Syndrome is essential for clinical practice and board examinations.
1. Severe Cutaneous Adverse Reactions (SCARs): SJS & TEN
Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) represent life-threatening, cell-mediated, cytotoxic hypersensitivity reactions characterized by widespread destruction and detachment of the epidermis and mucosal membranes.
Pathophysiology
Triggered predominantly by drugs, cytotoxic T-lymphocytes (CD8+) and natural killer (NK) cells induce massive keratinocyte apoptosis through two primary pathways:
Granulysin (a key cytotoxic protein secreted in blister fluid — single most important mediator).
Fas - Fas Ligand (FasL) interactions and Perforin/Granzyme B pathway.
Disease Spectrum & Staging
The distinction between SJS and TEN is based strictly on the percentage of Total Body Surface Area (TBSA) exhibiting epidermal detachment :
- Condition TBSA Epidermal Detachment Mucosa Involved Mortality Rate
- Stevens-Johnson Syndrome (SJS) < 10% TBSA ≥ 2 mucosal sites (90%) 1% – 5%
- SJS / TEN Overlap 10% – 30% TBSA ≥ 2 mucosal sites (100%) 10% – 15%
- Toxic Epidermal Necrolysis (TEN) > 30% TBSA Severe involvement of multiple sites 25% – 50%
- High-Risk Offending Drugs (Mnemonic: SATAN )
- S : S ulfonamides (Cotrimoxazole / Trimethoprim-Sulfamethoxazole, Sulfasalazine)
- A : A ntiepileptics (Carbamazepine, Phenytoin, Lamotrigine, Phenobarbital)
- T : T oxic NSAIDs (Oxicams: Piroxicam, Meloxicam)
- A : A llopurinol (especially in patients with renal impairment or HLA-B*5801 allele)
- N : N evirapine (NNRTI) / Non-nucleoside reverse transcriptase inhibitors
- Clinical Features & Characteristic Signs
Prodrome : High-grade fever, malaise, sore throat, and conjunctivitis preceding skin lesions by 1 to 3 days.
Cutaneous Lesions : Dusky erythematous macules, targetoid atypical papules, coalescing into flaccid bullae that rupture, leaving extensive denuded, scalded-appearing dermis.
Mucosal Involvement : Severe erosions of ocular (purulent conjunctivitis, corneal ulceration, symblepharon), oral (crusted hemorrhagic lips, painful stomatitis), and anogenital mucosa.
Physical Signs :
Nikolsky Sign : Positive (dislodgement of intact superficial epidermis by light lateral sliding manual pressure on unblistered skin).
Asboe-Hansen Sign : Positive (extension of a bulla laterally into unblistered skin when direct vertical pressure is applied to the roof of the bulla).
Management Protocol
Immediate Withdrawal : Stop all non-essential and potentially culprit medications instantly.
Supportive Care : Transfer to a Specialized Burn Unit or ICU . Maintain room temperature at 30–32°C.
Fluid & Electrolyte Balance : Warmed Ringer's Lactate (calcified using modified Parkland formula; fluid requirements are typically 2/3 of thermal burn requirements due to less edema).
Ophthalmologic Care : Daily examination by an ophthalmologist; lubricating eye drops, topical antibiotic drops, and breaking of synechiae to prevent permanent blindness and symblepharon .
Specific Immunomodulatory Therapy : Cyclosporine (3–5 mg/kg/day), High-dose IVIG (Intravenous Immunoglobulin 1 g/kg/day for 3 days), or Plasma Exchange (Plasmapheresis). Prophylactic systemic antibiotics are NOT recommended.
- 2. Cutaneous Markers of Systemic Internal Diseases
- A. Erythema Nodosum (EN)
Erythema Nodosum is a hypersensitivity reaction involving the subcutaneous fat (septal panniculitis without vasculitis).
Clinical Presentation : Painful, tender, warm, erythematous, non-ulcerating nodules situated symmetrically over the anterior shins (tibial surfaces) . Lesions evolve over 2–8 weeks like a bruise (changing from red/purple to yellowish-green / erythema contusiformis ).
Major Systemic Etiologies (Mnemonic: SHINS) :
S : Sarcoidosis (Löfgren Syndrome triad: Erythema Nodosum + Bilateral Hilar Lymphadenopathy + Acute Polyarthralgia).
H : Histoplasmosis / Fungal infections.
I : Infections (Streptococcal pharyngitis - most common cause in children ; Primary Tuberculosis; Leprosy - Erythema Nodosum Leprosum / ENL Type 2 reaction).
N : No cause identified (Idiopathic in up to 50% of cases).
S : Systemic Inflammatory Bowel Disease (Ulcerative Colitis & Crohn's Disease) / Sulfonamides & Oral Contraceptive Pills.
B. Other High-Yield Cutaneous Manifestations
Cutaneous Condition Morphological Features Associated Systemic Disease
Acanthosis Nigricans Hyperpigmented, velvety, hyperkeratotic plaques in intertriginous areas (neck, axillae, groin) Insulin Resistance (Type 2 DM, PCOS, Obesity); Gastrointestinal Malignancy (Gastric Adenocarcinoma - if rapid onset / tripe palms )
Pyoderma Gangrenosum Extremely painful, rapidly enlarging ulcer with purplish/violaceous, undermined, rolled edges; exhibits pathergy Inflammatory Bowel Disease (Ulcerative Colitis > Crohn's), Rheumatoid Arthritis, Acute Myeloid Leukemia
Erythema Multiforme (EM) Typical targetoid lesions (3 concentric rings: central dusky blister, pale edematous zone, outer erythematous ring) Infections: Herpes Simplex Virus (HSV 1 & 2) (90% of cases), Mycoplasma pneumoniae
Erythema Gyratum Repens Wood-grain pattern of concentric erythematous rings with fine trailing scale, rapidly migrating Malignancy (Paraneoplastic marker: Bronchogenic Carcinoma, Esophageal Carcinoma)
3. Delirium vs. Dementia in General Hospital Wards
Distinguishing acute Delirium from Dementia is one of the most critical bedside skills in internal medicine wards.
Differential Features Matrix
- Diagnostic Feature Delirium (Acute Confusional State) Dementia (Major Neurocognitive Disorder)
- Onset Acute (hours to days) Insidious (months to years)
Course Fluctuating over 24 hours (lucid intervals, evening worsening / "sundowning") Progressive, stable day-to-day decline
Consciousness / Alertness Impaired / Altered (reduced, hyperalert, or lethargic) Intact until very late stages
Attention Severely Impaired (inability to focus, sustain, or shift attention) Relatively intact in early/moderate stages
Memory Immediate & short-term memory impaired secondary to inattention Short-term memory severely impaired early; remote memory lost late
Perception Frequent visual hallucinations and illusions Hallucinations absent until late stages (except DLB)
Reversibility Potentially Reversible once underlying cause is treated Usually Irreversible (progressive neurodegeneration)
Common Precipitating Causes of Delirium (Mnemonic: DELIRIUMS )
D : D rugs (Anticholinergics, Benzodiazepines, Sedatives, Opioids, Steroids, Polypharmacy).
E : E lectrolyte Imbalance (Hyponatremia, Hypercalcemia, Hypomagnesemia).
L : L ack of drugs (Alcohol or Benzodiazepine Withdrawal).
I : I nfection (Urinary Tract Infection, Pneumonia, Meningitis, Sepsis).
R : R educed sensory input / R etention (Urinary retention, Severe constipation).
I : I ntracranial pathology (Acute Ischemic Stroke, Subdural Hematoma, Encephalopathy).
U : U remia / Hepatic Failure / Hypoxia.
M : M etabolic disturbances (Hypoglycemia, Diabetic Ketoacidosis, Thyroid storm).
S : S leep deprivation / Post-operative state.
4. Neuroleptic Malignant Syndrome (NMS) vs. Serotonin Syndrome
Both NMS and Serotonin Syndrome are life-threatening, drug-induced hyperthermic emergencies encountered in medical and psychiatric wards. A precise distinction is vital because their pharmacological treatments differ completely.
Comprehensive Comparison Matrix
Clinical Parameter Neuroleptic Malignant Syndrome (NMS) Serotonin Syndrome
Etiology Dopamine D2 receptor blockade or abrupt withdrawal of dopamine agonists (Levodopa) Excessive central and peripheral serotonergic neurotransmission (5-HT1A / 5-HT2A)
Causal Agents Typical Antipsychotics (Haloperidol, Fluphenazine), Atypical Antipsychotics (Olanzapine, Risperidone), Metoclopramide SSRIs, SNRIs, MAOIs, TCAs, Tramadol, Linezolid, Fentanyl, MDMA ("Ecstasy"), St. John's Wort
Onset Subacute / Slow (develops over 1 to 3 days or weeks after drug initiation/dose escalation) Rapid / Acute (develops within 6 to 24 hours of drug initiation or combination)
Neuromuscular Signs Severe generalized "Lead-pipe" Rigidity , bradykinesia, hyporeflexia Hyperreflexia , Clonus (spontaneous, inducible, or ocular clonus), Tremor, Akathisia (Legs > Arms)
Gastrointestinal Bowel sounds normal or decreased; no diarrhea Hyperactive bowel sounds , abdominal cramps, profuse diarrhea
- Pupils Normal or sluggish Mydriasis (dilated pupils), diaphoresis
- Temperature Extreme Hyperthermia (often > 40°C / 104°F) Hyperthermia (mild to severe depending on toxicity)
Laboratory Profile Marked elevation of Creatine Kinase (CK) (> 1,000–10,000+ U/L), Leukocytosis (10,000–40,000/mm³), Myoglobinuria Normal or mildly elevated CK; normal WBC
Specific Antidote Dantrolene (IV skeletal muscle relaxant) AND Bromocriptine / Amantadine (Dopamine agonist) Cyproheptadine (Oral 5-HT1A / 5-HT2A receptor antagonist)
Emergency Management Guidelines
NMS Management :
Immediately discontinue all causative antipsychotic agents.
Initiate aggressive external cooling (cooling blankets, ice packs in axillae/groin) and IV fluid hydration to prevent renal failure from rhabdomyolysis.
Administer Dantrolene (1 to 2.5 mg/kg IV bolus, max 10 mg/kg/day) to reduce muscle rigidity and heat generation.
Administer Bromocriptine (2.5 to 5 mg orally/NG tube every 8 hours) to restore central dopaminergic tone.
Serotonin Syndrome Management :
Immediately discontinue all serotonergic agents.
Provide supportive care and IV Benzodiazepines (Diazepam 5–10 mg IV) to control agitation, seizures, and muscle twitching.
Administer Cyproheptadine (Initial dose: 12 mg orally/NG tube, followed by 2 mg every 2 hours if symptoms persist; maintenance 4–8 mg q6h).